## 1 Clinical outcomes after viraemia among people receiving dolutegravir versus efavirenz-

## 2 based first-line antiretroviral therapy in South Africa

- 3 Authors: Kwabena Asare<sup>1,6</sup>, Lara Lewis<sup>1</sup>, Johan van der Molen<sup>1</sup>, Yukteshwar Sookrajh<sup>2</sup>,
- 4 Thokozani Khubone<sup>2</sup>, Pravikrishnen Moodley<sup>3</sup>, Richard J Lessells<sup>1,4</sup>, Kogieleum Naidoo<sup>1,5</sup>,
- 5 Phelelani Sosibo<sup>2</sup>, Nigel Garrett<sup>1,6</sup> and Jienchi Dorward<sup>1,7</sup>

### 6 Institutions

- Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South
   Africa.
- 9 2. eThekwini Municipality Health Unit, eThekwini Municipality, Durban KwaZulu-Natal,
   10 South Africa
- 11 3. Department of Virology, University of KwaZulu-Natal and National Health Laboratory
- 12 Service, Inkosi Albert Luthuli Central Hospital, Durban, KwaZulu-Natal, South Africa
- KwaZulu-Natal Research and Innovation Sequencing Platform (KRISP), University of
   KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa
- South African Medical Research Council (SAMRC)-CAPRISA-TB-HIV Pathogenesis and
   Treatment Research Unit, University of KwaZulu-Natal Nelson R Mandela School of
   Medicine, Durban, South Africa
- Discipline of Public Health Medicine, School of Nursing and Public Health, University of
   KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa
- Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxfordshire,
   United Kingdom
- 22
- 23 Corresponding author: Mr Kwabena Asare, MSc. Centre for the AIDS Programme of Research
- 24 in South Africa. Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine,
- 25 University of KwaZulu-Natal, Private Bag X7, Congella, 4013, South Africa.
- 26 Telephone: +27 31 260 4453; E-mail: kwabena.asare@caprisa.org

### 27 Abstract

28 Introduction. We aimed to compare clinical outcomes after viraemia between dolutegravir

- 29 versus efavirenz-based first-line antiretroviral therapy (ART) as evidence is lacking outside
- 30 clinical trials in resource-limited settings.
- 31 **Methods**. We conducted a retrospective cohort analysis with routine data from 59 South African
- 32 clinics. We included people living with HIV ≥15 years old receiving first-line tenofovir disoproxil
- 33 fumarate, lamivudine, dolutegravir (TLD) or tenofovir disoproxil fumarate, emtricitabine,
- 34 efavirenz (TEE), and with first viraemia (≥50 copies/ml) between June to November 2020. We
- 35 used multivariable modified Poisson regression models to compare retention-in-care and viral
- 36 suppression (<50 copies/ml) after 12 months between participants on TLD versus TEE.
- 37 **Results**. At first viraemia, among 9657 participants, 6457 (66.9%) were female, median age
- 38 was 37 years (interquartile range [IQR] 31-44); 7598 (78.7%) were receiving TEE and 2059
- 39 (21.3%) TLD. Retention-in-care was higher in the TLD group (84.9%) than TEE (80.8%),
- 40 adjusted risk ratio (aRR) 1.03, 95%CI 1.00-1.06. Of 6569 participants retained in care and had a
- 41 12-month viral load, viral suppression was similar between TLD (78.9%) and TEE (78.8%)
- 42 groups, aRR 1.02, 95%CI 0.98-1.05. However, 3368 participants changed ART during follow-up;
- 43 the majority from TEE to first-line TLD (89.1%) or second-line (TLD 3.4%,
- 44 zidovudine/emtricitabine/lopinavir-ritonavir 2.1%). In sensitivity analysis among the remaining
- 45 3980 participants who did not change ART during follow-up and had a 12-month viral load, viral
- 46 suppression was higher in the TLD group (78.9%) than TEE (74.9%), aRR 1.07, 95%CI 1.03-
- 47 1.12.
- 48 **Conclusions**. Among people with viraemia on first-line ART, dolutegravir was associated with
- 49 better retention-in-care and similar or better viral suppression than efavirenz.
- 50 **Keywords**: Antiretroviral therapy; dolutegravir; retention-in-care; viraemia; viral suppression.

# 51 INTRODUCTION

- 52 In South Africa, about 23% of people living with HIV (PLHIV) experience an episode of viraemia
- 53 during first-line antiretroviral therapy (ART)[1]. Persistent viraemia during ART in PLHIV is
- 54 usually due to inconsistent adherence[2, 3] or drug resistance[3-5] and increases the risk of
- 55 virologic or treatment failure[6, 7]. This often leads to a slower immune reconstitution[8] and a
- 56 higher incidence of all-cause mortality[9-11].
- 57 Dolutegravir is an integrase strand transfer inhibitor (INSTI) being rolled out for ART in South
- 58 Africa since 2019[12] and in most low- and middle-income countries (LMICs)[13], replacing the
- 59 previous drug efavirenz. Compared to efavirenz and other non-nucleoside reverse transcriptase
- 60 (NNRTI) based regimens, dolutegravir is more effective and tolerable with an increased genetic
- 61 barrier against drug resistance based on clinical trial evidence[14-18]. Accordingly, people
- 62 receiving first-line dolutegravir-based regimens who present with viraemia may be more likely to
- 63 have inconsistent treatment adherence rather than drug resistance and could be more likely to
- 64 virally re-suppress without the need for changing regimens, unlike people receiving
- 65 efavirenz[19].
- 66 Based on these therapeutic strengths of dolutegravir, the World Health Organisation 2021 ART
- 67 treatment guidelines recommend delaying switching to second-line ART in people with
- 68 virological failure on first-line dolutegravir-based regimens[20]. This contrasts with
- 69 recommendations for an early switch to second-line ART among people with virological failure
- 70 receiving first-line efavirenz and other NNRTI-based regimens[20]. However, there is limited
- 71 evidence from routine healthcare settings on clinical outcomes and viral load trajectories after
- viraemia in people receiving first-line dolutegravir-based ART from high HIV prevalence settings
- in LMICs.
- 74 Therefore, we aimed to assess retention-in-care and viral load trajectories after viraemia in
- 75 people receiving first-line dolutegravir-based ART compared to those receiving efavirenz.
- 76

# 77 METHODS

# 78 Study design and setting

- 79 We conducted a retrospective cohort study with de-identified, routinely collected data from 59
- 80 public, primary healthcare facilities in eThekwini Municipality, KwaZulu-Natal, South Africa. In
- 81 these clinics, viral load testing is done at 6 and 12 months after ART initiation and then 12-

- 82 monthly thereafter[12]. CD4 count is routinely measured at ART initiation and after 12 months
- and subsequently repeated if clinically indicated (e.g., viral load  $\geq$ 1000 copies/ml).
- 84 The 2019 South African HIV treatment guideline[12] recommends that PLHIV with a viral load
- 85 ≥50 copies/ml during first-line ART should receive enhanced adherence counselling, and a
- 86 repeat viral load should be performed after two to three months. People receiving first-line ART
- 87 with two consecutive viral loads ≥1000 copies/ml two to three months apart are classified as
- 88 having virological failure, and switching to second-line ART is recommended if they were
- 89 receiving an NNRTI-based regimen including efavirenz or nevirapine. However, for those
- 90 receiving dolutegravir, switching to second-line ART is only recommended after two years of
- 91 ongoing viraemia.
- 92 This study was approved by the Biomedical Research Ethics Committee of the University of
- 93 Kwazulu-Natal (BE646/17), the KwaZulu-Natal Provincial Health Research Ethics Committee
- 94 (KZ\_201807\_021), the TB/HIV Information Systems Data Request Committee, and the
- 95 eThekwini Municipality Health Unit.

# 96 Data sources and data management

- 97 The data source for this study was South Africa's TIER.Net electronic database which contains
- 98 demographics, clinical status, regimen and clinic visit information of people receiving ART in
- 99 public sector healthcare clinics[21]. All datasets were de-identified by the South African National
- 100 Department of Health's TB/HIV Information Systems (THIS-www.tbhivinfosys.org.za/) before
- 101 access and use. We performed data cleaning to remove duplicate entries and rationalize ART
- 102 regimen lines according to clinical guidelines.

# 103 **Participants**

- 104 The study cohort included PLHIV aged ≥15 years with first viraemia (viral load ≥50 copies/ml)
- 105 between June 01, 2020, and November 30, 2020, while receiving first-line TEE or TLD
- 106 regimens. The TLD group included participants who initiated TLD and who transitioned from an
- 107 NNRTI-based regimen to TLD before viraemia. The ART regimen lines were based on a
- 108 predefined variable from the TIER.Net dataset, prevailing guidelines, and clinical considerations.
- 109 For example, someone who transitioned from TEE to TLD with two previous viral loads ≥1000
- 110 copies/ml was reclassified as second-line TLD. The ART regimen at viraemia was defined as
- 111 the regimen participants were receiving at the time of viraemia, so all participants who
- 112 transitioned from TEE to TLD on the date of viraemia were classified as being on TEE at the
- 113 time of viraemia. We selected the baseline period of viraemia to include as many participants as

- 114 possible on dolutegravir as implementation started in December 2019 and to allow a minimum
- of 365 days (12 months) plus 90 days of follow-up before the data cutoff of our dataset on April
- 116 30, 2022. We excluded participants who had been receiving their ART regimen at the time of
- 117 viraemia for less than 90 days and those not receiving standard first-line regimens of TEE or
- 118 TLD at the time of viraemia.

### 119 **Primary outcomes**

- 120 Our primary outcomes were retention-in-care and viral suppression at 12 months follow-up after
- 121 viraemia. Retention-in-care at 12 months was defined as not being lost to follow-up or recorded
- 122 in TIER.Net as either deceased or 'transferred out' to another clinic (as we could not access or
- 123 link to data at other clinics to establish subsequent retention-in-care) by 365 days after viraemia.
- 124 Loss to follow-up was defined based on the South African ART programme guidelines of being
- 125 ≥90 days late for a visit[22]. Viral suppression was defined as viral load <50 copies/ml.
- 126 Considering viral loads are not always completed on time in routine care, we defined the 12-
- 127 month window as the closest viral load to 365 days between 181 to 545 days after viraemia. We
- 128 included only the viral loads of participants retained in care.

### 129 Secondary outcomes

- 130 To assess implementation fidelity to the guidelines for managing viraemia, we evaluated the
- 131 secondary outcomes of clinic visit attendance up to 6 months after viraemia and 3-month repeat
- 132 viral load completion and viral suppression (<50 copies/ml). We defined the 3-month viral load
- 133 window as the closest viral load testing date to 90 days between 28 to 180 days after viraemia.

# 134 Exposures

- 135 The primary exposure was the first-line ART regimen combination (TLD versus TEE) that
- 136 participants were receiving at the time of viraemia. Potential confounders included participant
- 137 characteristics at viraemia, including age, gender, active tuberculosis disease, viral load
- 138 category, CD4 count category, and time-period of viraemia.

### 139 Statistical analyses

- 140 We performed all statistical analyses using R 4.2.0 (R Foundation for Statistical Computing,
- 141 Vienna, Austria)[23]. We used modified Poisson regression models with robust standard errors
- adjusting for clustering by clinic[24] to determine the risk ratios of retention-in-care at 12 months
- 143 and viral suppression at 3 and 12 months after viraemia. In all regression models, we compared
- 144 TLD versus TEE first-line regimens and adjusted for participant characteristics at viraemia: age,

gender, active tuberculosis disease, time-period of viraemia, viral load category and CD4 countcategory.

- 147 We performed two separate sensitivity analyses. The first sensitivity analysis involved the 12-
- 148 month retention-in-care outcome, where we included participants who were transferred out to
- another clinic as being retained in care. The second sensitivity analysis involved the 12-month
- 150 viral suppression outcome, where we excluded participants who changed their ART regimen
- 151 during the 12-month follow-up.
- 152 To better understand management and outcomes among people with high-level viraemia, we
- 153 conducted a secondary analysis in participants with viraemia ≥1000 copies/ml. In this sub-
- group, we plotted a Sankey diagram to graphically present viral load trajectories after viraemia
- and switching to second-line ART (only in the TEE group). We only included participants with
- 156 complete 3- and 12-month viral load results for the Sankey diagram.
- 157

# 158 **RESULTS**

# 159 Cohort characteristics at the time of viraemia

160 Between June 01, 2020, and November 30, 2020, 11366 people aged ≥15 had viraemia while

receiving first-line ART at the study clinics (Figure 1). At the time of viraemia, 1389 had been
 receiving their current regimen for less than 90 days, and 320 participants were not receiving

- 163 standard TEE or TLD regimens and were excluded. Of the remaining 9657 people included in
- 164 the analyses, 7598 (78.7%) were receiving TEE, and 2059 (21.3%) were receiving TLD
- regimens at the time of viraemia (Table 1). In the TLD group, 584 (28.4%) had been initiated on
- 166 TLD, and 1475 (71.6%) had transitioned to TLD from an NNRTI-based regimen before viraemia.
- 167 The time on the current regimen was lower in the TLD group (0.5 years, IQR 0.4-0.5) than in the
- 168 TEE group (3.0 years, IQR 1.1-5.3). The median age of the cohort was 37 years (IQR 31-44),
- and 6457 (66.9%) were female, of whom 196 (3.0%) were pregnant. There were more females
- 170 (n=5624, 74.0%) in the TEE group and more males (n=1226, 59.5%) in the TLD group.

# 171 Clinical outcomes after viraemia

- 172 Twelve months after viraemia, 1183 (12.3%) participants were recorded as lost to follow-up, 59
- 173 (0.6%) had died, 528 (5.5%) had transferred out to another clinic, and 7887 (81.7%) were
- 174 retained in care (Table 2). Retention-in-care at 12 months was 80.8% (n=6139) in the TEE
- 175 group and 84.9% (n=1748) in the TLD group (Table 2). In the multivariable Poisson regression
- 176 analysis adjusted for age, gender, active tuberculosis disease, time-period of viraemia, viral load

177 category and CD4 count category, all at the time of viraemia, 12-month retention-in-care was

- higher in the TLD group than TEE (adjusted risk ratio [aRR] 1.03, 95% confidence interval [CI]
- 179 1.00-1.06, p=0.047) (Table 3). In sensitivity analysis (Table S 1), where we classified people
- 180 who were transferred out to another clinic as being retained in care, 12-month retention-in-care
- 181 was similar between the TLD (89.1%) and TEE (86.6%) groups, aRR 1.02, 95% CI 0.99-1.04,
- 182 p=0.149.

Of participants retained in care at 12 months, 6569 (83.3%) had a follow-up viral load done at a median of 363 days (IQR, 320-384) after viraemia. By regimen, 5164 (84.1%) in the TEE group and 1405 (80.4%) in the TLD group had a 12-month viral load (Table 2). Of participants with a 12-month viral load, 4067 (78.8%) in the TEE group and 1108 (78.9%) in the TLD group were virally suppressed. The multivariable Poisson regression analysis showed no difference in 12month viral suppression in the TLD group versus TEE (aRR 1.02, 95% CI 0.98-1.05, p=0.418) (Table 4).

- 190 However, at a median of 189 days (IQR, 84-271) after viraemia, 3368 (34.9%) participants
- 191 changed their ART regimen (Table 2). Of these, 3074 (91.3%) transitioned to another first-line,
- and 294 (8.7%) switched to second-line regimens. Participants in the TEE group had more
- regimen changes after viraemia (n=3323, 43.7%) than those in the TLD group (n=45, 2.2%). In
- a sensitivity analysis among 3980 participants who did not change their regimen within 12
- 195 months after viraemia and had a 12-month viral load, 12-month viral suppression was more
- 196 likely in the TLD group (78.9%) than TEE (74.9%), aRR 1.07, 95% CI 1.03-1.12, p=0.001)
- 197 (Table 5).

198 We assessed implementation fidelity to viraemia management guidelines. In the first 6 months

- after viraemia, 7038 (92.6%) participants in the TEE group and 1848 (89.8%) in the TLD group
- 200 had at least one visit after a median of 85 (IQR, 69-107) and 86 (IQR, 77-111) days respectively.
- 201 Within the 6 months, participants in the TEE group had a median of 3 (IQR, 2-4) visits, and
- 202 participants in the TLD group had a median of 3 (IQR, 2-3) visits (Table 2). Regarding viral load
- 203 monitoring after viraemia, only 2961 (42.1%) participants in the TEE group and 780 (42.2%) in
- the TLD group had a 3-month repeat viral load done after a median of 112 (IQR, 87-141) and
- 205 120 (IQR, 96-161) days respectively. Three-month repeat viral load suppression was higher in
- 206 the TLD group (n=576,73.8%) than the TEE group (n=1962, 66.3%), aRR 1.07, 95% CI 1.02-
- 207 1.13, p=0.009; Table S 2).

7

- 208 We also assessed follow-up outcomes restricted to participants with high-level viraemia (≥1000
- 209 copies/ml). A total of 2163 participants presented with high-level viraemia, of whom 1804
- 210 (83.4%%) were receiving TEE and 359 (16.6%) were receiving TLD (Table S 3). Of these, 328
- 211 (34.7%) participants in the TEE group and 38 (20.0%) in the TLD group had a virological failure
- 212 (repeat 3-month viral load ≥1000 copies/ml). Of participants with virological failure in the TEE
- group, 104 (31.7%) were switched to second-line ART within the 12-month follow-up period
- 214 (from the time of viraemia). In the multivariable Poisson regression models, participants who
- were on TLD at the time of high-level viraemia had better outcomes than those on TEE
- 216 regarding 3-month viral suppression (63.7% versus 42.3%, aRR 1.39, 95% CI 1.22-1.58,
- 217 p<0.001, Table S 4), 12-month retention-in-care (71.9% versus 63.3%, aRR 1.11, 95% CI 1.02-
- 218 1.22, p=0.018, Table S 5) and 12-month viral suppression (76.6% versus 61.6%, aRR 1.24, 95%
- 219 CI 1.12-1.36, p<0.001, Table S 6). A graphical overview of outcomes after high-level viraemia is
- presented in the Sankey diagram in Figure 2.
- 221 In the Poisson regression analyses, outcomes were generally less likely among participants
- aged <25 at the time of viraemia than older participants.

### 223 Discussion

In this cohort study with large-scale ART programmatic data from 59 public sector healthcare

- 225 clinics in South Africa, retention-in-care after viraemia was better among PLHIV on first-line TLD
- than TEE. Viral suppression after viraemia was better among PLHIV, who stayed on first-line
- TLD than those who stayed on first-line TEE. Retention-in-care and viral suppression were
- better among participants with high-level viraemia (≥1000 copies/ml) on TLD than TEE.
- 229 Limited evidence exists on retention-in-care and viral suppression after viraemia on first-line
- 230 dolutegravir-based ART in routine LMIC settings, but such data is urgently needed to optimise
- 231 strategies for managing viraemia on dolutegravir. Evidence from clinical trials has shown lower
- rates of treatment discontinuation and abandonment due to lower rates of adverse events with
- 233 dolutegravir-based than efavirenz-based ART regimens[17, 18]. Our finding of better retention-
- in-care with TLD than TEE after viraemia on first-line ART is consistent with the results from
- these studies[17, 18]. It emphasises the potential effect of the tolerability of dolutegravir in
- ensuring consistent treatment adherence and improved clinical outcomes after viraemia.
- 237 For viral suppression after viraemia, we found one similar study conducted in South Africa
- among 385 participants enrolled in the ADVANCE trial who had viraemia while receiving first-
- 239 line dolutegravir-based or efavirenz-based ART regimens[19]. The study used a protocol-

240 defined virologic failure of either ≥1000 copies/ml at week 12, ≥200 copies/ml at week 24, or

241 ≥50 copies/ml at week 48 after enrolment. In participants with follow-up viral load available, viral

suppression (<50 copies/ml) within three follow-up visits after the first protocol-defined virologic

failure was 74.0% (n=77/104) with tenofovir alafenamide (TAF)/emtricitabine (FTC)/dolutegravir,

244 85.0% (n=85/100) with TDF/FTC/dolutegravir and 40.4% (n=44/109) with

245 TDF/FTC/efavirenz[19]. This evidence from the ADVANCE trial is consistent with our findings

from routine healthcare settings, but the efavirenz group in the ADVANCE trial had lower viral

- suppression.
- 248 Our findings are essential in resource-limited settings approaching a full rollout to dolutegravir-

based regimens for monitoring implementation successes. We used South African guideline

250 definitions of viraemia, retention-in-care, and viral suppression and adjusted for potential

251 confounders of clinical outcomes after viraemia, such as age, gender, active tuberculosis

disease, time-period of viraemia, viral load and CD4 count. Our findings support 2019[12] and

253 current 2023[25] South African ART treatment guidelines that recommend the delay of switching

to second-line ART after virologic failure among participants receiving first-line dolutegravir-

255 based regimens since enhanced adherence counselling is more likely to lead to re-suppression

due to dolutegravir's efficacy[14] and increased genetic barrier to drug resistance[26].

257 Furthermore, our analysis on viraemia management revealed healthcare bottlenecks that can

be addressed to improve clinical outcomes after viraemia. Although about 90% of participants

had a clinic visit within the first 6 months after viraemia, less than half had a repeat 3-month viral

260 load. Some of these missing repeat viral loads might have been done but not recorded in

TIER.Net. However, studies in South Africa[27] and Lesotho[28] that used prospectively

collected clinic data have shown similar rates of 47.7% and 40.0% of repeat viral load

263 completion within 6 months after the first elevated viral load ≥1000 copies/ml in participants

264 receiving ART. These gaps lead to missed opportunities for adequate viraemia management,

such as confirming persistent viraemia and switching to second-line ART with potentially

266 negative implications for increased morbidity and mortality[29, 30].

Our analysis also revealed poorer retention-in-care and viral suppression outcomes among younger PLHIV. Younger people remain a high-risk group of the HIV epidemic[31], and these findings indicate they might also struggle to achieve better treatment outcomes during chronic HIV infection. Thus, engaging and paying particular attention to young people with viraemia on first-line ART might also be necessary as they likely have special needs that must be addressed for improved outcomes.

9

273 Our study had some limitations. Although most people currently initiating ART in South Africa 274 are prescribed dolutegravir-based regimens[32], new initiations on dolutegravir and the 275 transition from other regimens to dolutegravir are not random. People initiating or transitioning to 276 dolutegravir may be more likely to be clinically stable than people on different regimens, so we 277 adjusted for the viral load category at the time of viraemia in all regression models. However, we 278 cannot rule out confounding by variables not recorded in the dataset. The timing of viraemia 279 was also different as more participants in the TEE group were viraemic during the COVID-19 280 period and might have been at a higher risk of interruptions in care post-viraemia. However, we 281 adjusted for the time-period of viraemia in our analyses. This study is also at the early stages of 282 the dolutegravir implementation in South Africa, and more extended follow-up data are needed 283 as dolutegravir resistance may increase over time. Our analysis is also limited to one province, 284 and a national-level study would be more representative of the South African population. 285 In conclusion, our findings demonstrate that, among people with viraemia during first-line ART in

routine healthcare settings, dolutegravir use was associated with better retention-in-care and
better viral suppression among people who did not change ART regimen. Among people with
high-level viraemia ≥1000 copies/mL, TLD was even more strongly associated with improved
retention-in-care and viral suppression. Improving adherence to guidelines for managing
viraemia, including enhanced adherence counselling and repeat viral load monitoring, is
important for better outcomes with TLD after viraemia. Further research to investigate longerterm outcomes, such as switching to second-line ART after two years of ongoing viraemia on

first-line dolutegravir, would be a great addition to the evidence.

#### 294 **Notes**

- Author contributions. KA, YS, LL, JvdM, RJL, KN, NG and JD conceptualised the study. TK,
- 296 YS, PM, and PS managed data collection. TK, PS, and JvdM oversaw data curation. KA, YS,
- 297 TK, JvdM, PS, LL, RvH, NG and JD had full access to the data in the study. KA, JvdM, LL, and
- JD analysed the data. KA drafted the manuscript. All authors reviewed and approved the final
- 299 version for submission.
- Acknowledgements. We acknowledge the eThekwini Municipality Health Unit staff, patients,
   and primary care clinics.
- 302 **Financial support.** This work was supported with funding from the Africa Oxford Initiative
- 303 (AfiOx-160) and the Bill & Melinda Gates Foundation (INV-051067). JD, Academic Clinical
- 304 Lecturer (CL-2022-13-005), is funded by the UK National Institute of Health and Social Care
- 305 Research (NIHR). The views expressed in this publication are those of the author (s) and not
- 306 necessarily those of the NIHR, NHS or the UK Department of Health and Social Care.
- 307 **Potential conflicts of interest**. All authors declare no competing interests.

#### 308 References

309 1. Hermans LE, Moorhouse M, Carmona S, et al. Effect of HIV-1 low-level viraemia during 310 antiretroviral therapy on treatment outcomes in WHO-guided South African treatment 311 programmes: a multicentre cohort study. Lancet Infect Dis 2018; 18(2): 188-97. 312 2. Assemie MA, Alene M, Ketema DB, Mulatu S. Treatment failure and associated factors 313 among first line patients on highly active antiretroviral therapy in Ethiopia: a systematic 314 review and meta-analysis. Global Health Research and Policy **2019**; 4(1). 315 3. El-Khatib Z, Ekstrom AM, Ledwaba J, et al. Viremia and drug resistance among HIV-1 316 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. 317 AIDS 2010; 24(11): 1679-87. 318 Musengimana G, Tuvishime E, Kiromera A, et al. Acquired HIV drug resistance among 4. 319 adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-320 sectional nationally representative survey. Antivir Ther 2022; 27(3): 321 13596535221102690. 322 Henerico S, Mikasi SG, Kalluvya SE, et al. Prevalence and patterns of HIV drug 5. 323 resistance in patients with suspected virological failure in North-Western Tanzania. J 324 Antimicrob Chemother 2022; 77(2): 483-91. 325 6. Joya C, Won SH, Schofield C, et al. Persistent Low-level Viremia While on Antiretroviral 326 Therapy Is an Independent Risk Factor for Virologic Failure. Clin Infect Dis **2019**; 69(12): 327 2145-52. 328 Fleming J, Mathews WC, Rutstein RM, et al. Low-level viremia and virologic failure in 7. 329 persons with HIV infection treated with antiretroviral therapy. AIDS 2019: 33(13): 2005-330 12. 331 Deeks SG. Determinants of virological response to antiretroviral therapy: implications for 8. 332 long-term strategies. Clin Infect Dis 2000; 30 Suppl 2: S177-84. 333 9. Elvstam O, Medstrand P, Yilmaz A, Isberg PE, Gisslen M, Bjorkman P. Virological failure 334 and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral 335 treatment. PLoS One 2017; 12(7): e0180761. 336 10. Gupta-Wright A, Fielding K, van Oosterhout JJ, et al. Virological failure, HIV-1 drug 337 resistance, and early mortality in adults admitted to hospital in Malawi: an observational 338 cohort study. Lancet HIV 2020; 7(9): e620-e8. 339 11. Ayele TA, Worku A, Kebede Y, Alemu K, Kasim A, Shkedy Z. Choice of initial 340 antiretroviral drugs and treatment outcomes among HIV-infected patients in sub-Saharan

Africa: systematic review and meta-analysis of observational studies. Syst Rev 2017;

341

342 6(1): 173. 343 12. The South African National Department of Health. 2019 ART Clinical Guidelines for the 344 management of HIV in Adults, Pregnancy, Adolescents, Children, Infants and Neonates. 345 Available at: https://www.health.gov.za/wp-content/uploads/2020/11/2019-art-346 guideline.pdf. Accessed 12 June 2023. 347 13. World Health Organisation. WHO HIV policy adoption and implementation status in 348 countries. Available at: https://cdn.who.int/media/docs/default-source/hg-hiv-hepatitis-349 and-stis-library/who-hiv-policy-adoption-and-implementation-status-in-350 countries nov.pdf?sfvrsn=bb35e6ae 8. Accessed 25-May-2023. 351 14. Kanters S, Vitoria M, Zoratti M, et al. Comparative efficacy, tolerability and safety of 352 dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV 353 treatment: A systematic literature review and network meta-analysis. EClinicalMedicine 354 **2020**; 28: 100573. 355 Nickel K, Halfpenny NJA, Snedecor SJ, Punekar YS. Comparative efficacy, safety and 15. 356 durability of dolutegravir relative to common core agents in treatment-naïve patients 357 infected with HIV-1: an update on a systematic review and network meta-analysis. BMC 358 Infect Dis 2021; 21(1): 222. 359 16. Santoro MM. Di Carlo D. Armenia D. et al. Viro-immunological response of drug-naive 360 HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in 361 clinical practice. Antivir Ther 2018; 23(3): 249-57. 362 17. Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus Two Different Prodrugs of 363 Tenofovir to Treat HIV. New England Journal of Medicine 2019; 381(9): 803-15. 364 Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus Abacavir-Lamivudine for the 18. 365 Treatment of HIV-1 Infection. New England Journal of Medicine 2013; 369(19): 1807-18. 366 19. Pepperrell T, Venter WDF, McCann K, et al. Participants on Dolutegravir Resuppress 367 Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the 368 ADVANCE Trial. Clinical Infectious Diseases 2021; 73(4): e1008-e10. 369 20. World Health Organisation. Consolidated guidelines on HIV prevention, testing, 370 treatment, service delivery and monitoring: recommendations for a public health 371 approach. Available at: https://www.who.int/publications/i/item/9789240031593. 372 Accessed 25-May-2023.

373	21.	Osler M, Hilderbrand K, Hennessey C, et al. A three-tier framework for monitoring
374		antiretroviral therapy in high HIV burden settings. Journal of the International AIDS
375		Society <b>2014</b> ; 17(1): 18908.
376	22.	South Africa: National Department of Health. Adherence guidelines for HIV, TB and
377		NCDs: Policy and service delivery guidelines for linkage to care, adherence to treatment
378		and retention in care. 2016.
379	23.	R Core Team. R: A language and environment for statistical computing. Available at:
380		https://www.R-project.org/.
381	24.	Zou GY, Donner A. Extension of the modified Poisson regression model to prospective
382		studies with correlated binary data. Stat Methods Med Res 2013; 22(6): 661-70.
383	25.	The South African National Department of Health. 2023 ART Clinical Guidelines for the
384		Management of HIV in Adults, Pregnancy and Breastfeeding, Adolescents, Children,
385		Infants and Neonates. Available at: https://knowledgehub.health.gov.za/elibrary/2023-art-
386		clinical-guidelines-management-hiv-adults-pregnancy-and-breastfeeding-adolescents.
387		Accessed 10 July 2023.
388	26.	Llibre JM, Pulido F, García F, García Deltoro M, Blanco JL, Delgado R. Genetic barrier to
389		resistance for dolutegravir. AIDS Rev 2015; 17(1): 56-64.
390	27.	Fox MP, Brennan AT, Nattey C, et al. Delays in repeat HIV viral load testing for those
391		with elevated viral loads: a national perspective from South Africa. J Int AIDS Soc 2020;
392		23(7): e25542.
393	28.	Glass TR, Motaboli L, Nsakala B, et al. The viral load monitoring cascade in a resource-
394		limited setting: A prospective multicentre cohort study after introduction of routine viral
395		load monitoring in rural Lesotho. PLoS One 2019; 14(8): e0220337.
396	29.	Bell Gorrod H, Court R, Schomaker M, Maartens G, Murphy RA. Increased Mortality
397		With Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South Africa.
398		JAIDS Journal of Acquired Immune Deficiency Syndromes 2020; 84(1): 107-13.
399	30.	Bell-Gorrod H, Fox MP, Boulle A, et al. The Impact of Delayed Switch to Second-Line
400		Antiretroviral Therapy on Mortality, Depending on Definition of Failure Time and CD4
401		Count at Failure. American Journal of Epidemiology 2020; 189(8): 811-9.
402	31.	Risher KA, Cori A, Reniers G, et al. Age patterns of HIV incidence in eastern and
403		southern Africa: a modelling analysis of observational population-based cohort studies.
404		The Lancet HIV <b>2021</b> ; 8(7): e429-e39.

14

- 405 32. Dorward J, Sookrajh Y, Khubone T, et al. Implementation and outcomes of dolutegravir-
- 406 based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective
- 407 cohort study. The Lancet HIV **2023**.

408

# 409 Figure legends

- 410 **Figure 1.** Flow diagram of PLHIV receiving antiretroviral therapy at 59 clinics in South Africa.
- 411 ART=Antiretroviral therapy, ml=Milliliter, PLHIV=People living with HIV, TEE=Tenofovir disoproxil
- 412 fumarate plus emtricitabine plus efavirenz, TLD=Tenofovir disoproxil fumarate plus lamivudine
- 413 plus dolutegravir.
- 414 **Figure 2**. Sankey diagram showing the flow of viraemia management outcomes in PLHIV with
- 415 high-level viraemia (≥1000 copies/ml) while receiving first-line antiretroviral therapy for ≥90 days
- 416 at the time of viraemia. Panel (A) TLD group and panel (B) TEE group. ml=Milliliter,
- 417 PLHIV=People living with HIV, TEE=Tenofovir disoproxil fumarate plus emtricitabine plus
- 418 efavirenz, TLD=Tenofovir disoproxil fumarate plus lamivudine plus dolutegravir, VL=Viral load
- 419 (copies/ml).

### e 1





A. TLD group

e characteristics of people with viraemia (≥50 copies/ml)	while receiving first-line	ART		
		ART regimen at th	ART regimen at the time of	
Variable	Overall,	TEE,		
	N = 9,657	N = 7,598		
Age in years, median (IQR)	37 (31-44)	36 (30-43)		
Age in years				
15-24	717 (7.4%)	601 (7.9%)		
25-34	3,234 (33.5%)	2,727 (35.9%)	Ę	
35-44	3,455 (35.8%)	2,690 (35.4%)	7	
45+	2,251 (23.3%)	1,580 (20.8%)	E	
Gender				
Male	3,200 (33.1%)	1,974 (26.0%)	1,	
Female	6,457 (66.9%)	5,624 (74.0%)	5	
Known pregnant (females only)	196 (3.0%)	188 (3.3%)		
Known active tuberculosis disease	103 (1.1%)	69 (0.9%)		
Baseline time-period of viraemia				
June 2020	730 (7.6%)	703 (9.3%)		
July 2020	1,116 (11.6%)	1,018 (13.4%)		
August 2020	2,144 (22.2%)	1,796 (23.6%)	3	
September 2020	2,562 (26.5%)	1,996 (26.3%)	Ę	
October 2020	1,704 (17.6%)	1,222 (16.1%)	2	
November 2020	1,401 (14.5%)	863 (11.4%)	Ę	
TLD group category				
ted with TLD at ART initiation before viraemia	584 (28.4%)	-	Ę	
from an NNRTI-based regimen to TLD before viraemia	1,475 (71.6%)	-	1,	
ers since ART initiation, median (IQR)	4.0 (1.1-6.8)	4.0 (1.5-6.9)	3	
's on current ART regimen, median (IQR)	2.0 (0.5-4.9)	3.0 (1.1-5.3)	(	
Viral load at viraemia (copies/ml)				
50-199	4,650 (48.2%)	3,550 (46.7%)	1,	
200-999	2,844 (29.5%)	2,244 (29.5%)	6	
1000-	2 163 (22 4%)	1 804 (23 7%)		

# mes after viraemia (≥50 copies/ml) in people receiving first-line ART

		ART regimen		
Variable	<b>Overall</b> , N = 9,657	<b>TEE</b> , N = 7,598		
t least one ART visit within 6 months	8,886 (92.0%)	7,038 (92.6%)		
of ART visits within 6 months, median (IQR)	3 (2-3)	3 (2-4)		
first ART visit within 6 months, median (IQR)	85 (70-108)	85 (69-107)		
Repeat 3-month viral load test done <sup>a</sup>	3,741 (42.1%)	2,961 (42.1%)		
to repeat 3-month viral load, median (IQR)	113 (89-145)	112 (87-141)		
Repeat 3-month viral load (copies/ml)				
<50	2,538 (67.8%)	1,962 (66.3%)		
50-199	445 (11.9%)	344 (11.6%)		
200-999	288 (7.7%)	241 (8.1%)		
1000+	470 (12.6%)	414 (14.0%)		
RT regimen change within 12 months	3,368 (34.9%)	3,323 (43.7%)		
e changed to (of participants who changed regimen)				
1	3,074 (91.3%)	3,040 (91.5%)		
2	294 (8.7%)	283 (8.5%)		
n change within 12 months (of participants who changed regimen)	189 (84-271)	189 (83-272)		
to within 12 months (of participants who changed regimen)				
TEE (1st-line)	16 (0.5%)	0 (0.0%)		
TLD (1st-line)	3,001 (89.1%)	3,001 (90.3%)		
Other (1st-line)	57 (1.7%)	39 (1.2%)		
AZT/XTC/LPV/r (2nd-line)	72 (2.1%)	66 (2.0%)		
AZT/XTC/DTG (2nd-line)	81 (2.4%)	78 (2.3%)		
TLD (2nd-line)	116 (3.4%)	116 (3.5%)		
Other (2nd-line)	25 (0.7%)	23 (0.7%)		
Follow-up outcome at 12 months				
Lost to follow-up	1,183 (12.3%)	967 (12.7%)		
Died	59 (0.6%)	50 (0.7%)		
Transforred out to another alinia	570 (5 50/ )	110 (E 00/ )		

### Table 3

ultivariable Poisson regression models of factors associated with retention-in-care at 12 months follow-up after viraemia (3657)

				-	
<b>;</b>	Level	Retention-in-care at 12 months follow-up n/N (%)	Unadjusted RR (95% CI)	P value	
at viraemia	TEE	6139/7598 (80.8)	1	-	
	TLD	1748/2059 (84.9)	1.04 (1.01-1.07)	0.012	1.
emia	15-24	485/717 (67.6)	1	-	
	25-34	2479/3234 (76.7)	1.13 (1.08-1.18)	<0.001	1.
	35-44	2939/3455 (85.1)	1.25 (1.19-1.30)	<0.001	1.
	45+	1984/2251 (88.1)	1.29 (1.22-1.35)	<0.001	1.
,	Male	2573/3200 (80.4)	1	-	
	Female	5314/6457 (82.3)	1.03 (1.01-1.06)	0.007	1.
disease at viraemia	No	7821/9554 (81.9)	1	-	<u> </u>
	Yes	66/103 (64.1)	0.78 (0.69-0.89)	<0.001	0.
viraemia	June to July 2020	1431/1846 (77.5)	1	-	<u> </u>
	August 2020	45+ $1984/2251 (88.1)$ $1.29 (1.22-1.35)$ $<0.001$ Male $2573/3200 (80.4)$ $1$ $-$ Female $5314/6457 (82.3)$ $1.03 (1.01-1.06)$ $0.007$ No $7821/9554 (81.9)$ $1$ $-$ Yes $66/103 (64.1)$ $0.78 (0.69-0.89)$ $<0.001$ $e$ to July 2020 $1431/1846 (77.5)$ $1$ $-$ August 2020 $1799/2144 (83.9)$ $1.07 (1.03-1.11)$ $<0.001$ ptember 2020 $2173/2562 (84.8)$ $1.09 (1.05-1.12)$ $<0.001$ $e$ to be 2020 $1108/1401 (79.1)$ $1.01 (0.97-1.06)$ $0.541$ $0.50199$ $4087/4650 (87.9)$ $1$ $-$	1.		
	September 2020	2173/2562 (84.8)	1.09 (1.05-1.12)	<0.001	1.
	October 2020	1376/1704 (80.8)	1.03 (1.00-1.07)	0.051	1.
	November 2020	1108/1401 (79.1)	1.01 (0.97-1.06)	0.541	0.
s/ml) at viraemia	50-199	4087/4650 (87.9)	1	-	
	200-999	2400/2844 (84.4)	0.96 (0.94-0.98)	<0.001	0.
	1000+	1400/2163 (64.7)	0.74 (0.71-0.78)	<0.001	0.
s/µl) at viraemia	≤ 200	1088/1393 (78.1)	1	-	
	201-350	1466/1803 (81.3)	1.04 (1.01-1.08)	0.018	1.
	351-500	1555/1881 (82.7)	1.07 (1.04-1.10)	<0.001	1.
	> 500	2685/3194 (84.1)	1.08 (1.05-1.12)	<0.001	1.
	Missing	1093/1386 (78.9)	1.02 (0.97-1.06)	0.461	1.
		1		1	

erwise stated. <sup>a</sup> The primary exposure effect (retention-in-care at 12 months) is adjusted for all other variables in the tab  $\mu$ I=Microliter, mI=Milliliter, RR=Risk ratio, TEE=Tenofovir disoproxil fumarate plus emtricitabine plus efavirenz, TLD=Ter gravir.

#### Table 4

ultivariable Poisson regression models of factors associated with viral suppression at 12 months follow-up after viraemia were retained-in-care at 12 months follow-up and had viral load done (N=6569)

e	Level	Viral suppression (<50 copies/ml) at 12 months n/N (%)	Unadjusted RR (95% CI)	P value	F
at viraemia	TEE	4067/5164 (78.8)	1	-	
	TLD	1108/1405 (78.9)	1.00 (0.97-1.04)	0.915	1.
emia	15-24	281/398 (70.6)	1	-	
	25-34	1572/2050 (76.7)	1.08 (1.01-1.16)	0.022	1.
	35-44	1979/2480 (79.8)	1.12 (1.06-1.19)	P value         -         0.915         -         0.022         <0.001	1.
	45+	1343/1641 (81.8)	1.15 (1.08-1.23)	<0.001	1.
r	Male	1631/2086 (78.2)	1	-	
	Female	3544/4483 (79.1)	1.01 (0.98-1.05)	0.380	1.
disease at viraemia	No	5139/6514 (78.9)	1	-	
	Yes	36/55 (65.5)	0.83 (0.70-0.99)	0.038	0.
viraemia	June to July 2020	968/1229 (78.8)	1	-	
	August 2020	1301/1555 (83.7)	1.07 (1.02-1.11)	RR       P value $ -$ 04)       0.915 $ -$ 16)       0.022         19)       <0.001	1.
	September 2020	1476/1845 (80.0)	1.02 (0.97-1.07)	0.415	0.
at viraemia emia r disease at viraemia viraemia es/ml) at viraemia	October 2020	822/1109 (74.1)	0.94 (0.90-0.99)	0.012	0.
	November 2020	608/831 (73.2)	0.93 (0.87-0.99)	0.017	0.
s/ml) at viraemia	50-199	2808/3385 (83.0)	1	-	
emia r disease at viraemia viraemia ss/ml) at viraemia ls/µl) at viraemia	200-999	1628/2033 (80.1)	0.97 (0.94-1.00)	0.042	0.
	1000+	739/1151 (64.2)	0.78 (0.74-0.81)	<0.001	0.
ls/µl) at viraemia	≤ 200	674/901 (74.8)	1	-	
	201-350	952/1205 (79.0)	1.06 (1.01-1.11)	0.023	1.0
	351-500	1018/1308 (77.8)	1.04 (0.98-1.10)	0.170	1.
	> 500	1838/2246 (81.8)	1.10 (1.04-1.15)	<0.001	1.
	Missing	693/909 (76.2)	1.02 (0.97-1.07)	0.384	1.0

erwise stated. <sup>a</sup> The primary exposure effect (viral suppression at 12 months) is adjusted for all other variables in the tak  $\mu$ I=Microliter, mI=Milliliter, RR=Risk ratio, TEE=Tenofovir disoproxil fumarate plus emtricitabine plus efavirenz, TLD=Ter gravir.

### Table 5

: Univariable and multivariable Poisson regression models of factors associated with viral suppression at 12 months folling first-line ART who did not change their ART regimen within 12 months, were retained in care at 12 months follow-up a

·	Level	Viral suppression (<50 copies/ml) at 12 months follow-up n/N (%)	Unadjusted RR (95% CI)	P value	
imen	TEE	1950/2604 (74.9)	1	-	
	TLD	1086/1376 (78.9)	1.05 (1.01-1.10)	0.007	1.
emia	15-24	161/246 (65.4)	1	-	
	25-34	890/1215 (73.3)	1.11 (1.00-1.23)	0.042	1
	35-44	1164/1493 (78.0)	1.18 (1.07-1.30)	0.001	1
	45+	821/1026 (80.0)	1.21 (1.10-1.33)	<0.001	1.
	Male	1006/1326 (75.9)	1	-	
	Female	2030/2654 (76.5)	1.01 (0.97-1.05)	0.527	1.
disease at viraemia	No	3015/3945 (76.4)	1	-	
	Yes	21/35 (60.0)	0.79 (0.61-1.01)	0.056	0
viraemia	June to July 2020	469/640 (73.3)	1	-	
	August 2020	747/917 (81.5)	1.11 (1.05-1.18)	<0.001	1.
	September 2020	903/1141 (79.1)	1.08 (1.02-1.15)	0.010	1.
	October 2020	510/712 (71.6)	0.98 (0.92-1.04)	0.433	0
	November 2020	407/570 (71.4)	0.97 (0.89-1.06)	0.490	0
s/ml) at viraemia	50-199	1715/2107 (81.4)	1	-	
	200-999	940/1222 (76.9)	0.95 (0.91-0.99)	0.009	0
	1000+	381/651 (58.5)	0.72 (0.67-0.78)	<0.001	0
s/µl) at viraemia	≤ 200	427/582 (73.4)	1	-	
	201-350	553/720 (76.8)	1.05 (0.98-1.12)	0.138	1.
	351-500	586/787 (74.5)	1.02 (0.94-1.10)	0.637	1.
	> 500	1077/1344 (80.1)	1.10 (1.04-1.16)	0.002	1
	Missing	393/547 (71.8)	0.98 (0.92-1.05)	0.604	0
					1

erwise stated. <sup>a</sup> The primary exposure effect (viral suppression at 12 months) is adjusted for all other variables in the tat µI=Microliter, mI=Milliliter, RR=Risk ratio, TEE=Tenofovir disoproxil fumarate plus emtricitabine plus efavirenz, TLD=Ter gravir.